REVEAL HPS-3 TIMI-55, 2017 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of anacetrapib versus placebo in high risk patients already taking statins

        Z

NCT01252953    N Engl J Med 2017;:  



Studied treatment anacetrapib 100mg daily
Control treatment placebo



Patients high risk patients already taking statins
Size30624



Blindness double-blind Inclusion period
Follow-up duration median 4 years Centers
Lost to FU geographical localisation
Primary endpoint coronary events Design Parallel groups



EndpointX1N1X0N0TE95% CI cardiovascular events - 30624 - 0 no data Cardiovascular death, myocardial infarction, stroke - 30000 - 0 no data Cardiovascular death - 30000 - 0 no data all cause death - 30000 - 0 no data Nonfatal myocardial infarction - 30000 - 0 no data coronary events - 30000 - 0 no data Nonfatal stroke - 30000 - 0 no data stroke - 30000 - 0 no data Coronary revascularization - 30000 - 0 no data CHD death - 30000 - 0 no data Carotid revascularization - 30000 - 0 no data0,22,01,0

Merck announced on june 26, 2017 that the REVEAL trial with anacetrapib had met its primary endpoint, significantly reducing the rate of coronary death, MI, and coronary revascularization

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 2017;:     [PMID: 28847206]   link to pdf   add to Mendeley  

Links

Merck Reveals Positive Findings For Its CETP Inhibitor

ClinicalTrial.gov record NCT01252953



Registering number NCT01252953 (see trial on clinicaltrials.gov)
Code Name

Comment: Full results of REVEAL will be presented on August 29 at the European Society of Cardiology meeting in Barcelona, Spain